Non-Alcoholic Steatohepatitis Clinical Trial
Official title:
Development of a Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children
The purpose of this study is to document how often specific genotypes known to be associated with adult-onset NASH (Non-Alcoholic Steatohepatitis) occur in a pediatric cohort and investigate whether these genotypes are associated with increased susceptibility to NASH.
NASH is a clinico-pathological entity characterized by the development of histological
changes of inflammation and fibrosis in the liver that are nearly identical to those induced
by excessive alcohol intake, but in the absence of alcohol abuse. Nonalcoholic
steatohepatitis occurs commonly children with additional comorbidities such as obesity and
diabetes mellitus. Paralleling the increasing prevalence of obesity and type 2 diabetes in
the pediatric population, nonalcoholic fatty liver disease (NAFLD) and especially its more
severe histological form NASH, is expected to become one of the most common causes of
end-stage liver disease in both children and young adults.
Although no genome wide association studies have been conducted in association with NASH to
date, individual candidate gene investigations have identified several genes associated with
increase susceptibility to NASH in adults including the microsomal triglyceride transfer
protein (MTP) which regulates the incorporation of triglycerides into apolipoprotein B and a
key enzyme for the assembly and secretion of VLDL from hepatocytes, the manganese superoxide
dismutase (MnSOD) gene which catalyzes the conversion of two molecules of superoxide anion,
a highly unstable ROS, into hydrogen peroxide and oxygen more stable ROS, and lastly,
phosphatidylethanolamine N-methyltransferase (PEMT) which is required for hepatic secretion
of triacylglycerol in very low density lipoproteins (VLDL).
We propose the following aim:
Aim 1: To document the frequency of specific genotypes, previously identified to be
associated with adult-onset NASH, in a purely pediatric cohort.
Aim 2: To investigate whether these genotypes are associated with increased susceptibility
to NASH and increased occurrence of fibrosis in the cohort of pediatric subjects. Our
hypothesis would be:
A significantly higher proportion of the polymorphisms would exist in those subjects with
NASH compared to controls.
Aim 3: To investigate the presence of other polymorphisms or other biomarker that are
indicative of pediatric NASH. Such that our secondary hypothesis would be:
Specific polymorphisms or biomarkers will be identified that will indicate a higher
probability of NASH.
;
Observational Model: Family-Based, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05945537 -
A Study of INI-822 in Healthy Volunteers and Participants With Non-alcoholic Steatohepatitis (NASH) or Presumed NASH
|
Phase 1 | |
| Recruiting |
NCT05462353 -
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH
|
Phase 2 | |
| Recruiting |
NCT05065593 -
The Effect of Aerobic and Resistant Exercise Training in Patients With Non-Alcoholic Steatohepatitis
|
N/A | |
| Terminated |
NCT04171765 -
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
|
Phase 2 | |
| Recruiting |
NCT04365855 -
The Olmsted NAFLD Epidemiology Study (TONES)
|
N/A | |
| Active, not recruiting |
NCT02912260 -
Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
|
Phase 2 | |
| Recruiting |
NCT06054815 -
Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH
|
Phase 2 | |
| Completed |
NCT02784444 -
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
|
Phase 2 | |
| Not yet recruiting |
NCT06160271 -
Study of Liver Fibrosis Stage Assessment by Fibroblast Activation Protein Imaging in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis
|
Phase 2 | |
| Active, not recruiting |
NCT05573204 -
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients With Non-alcoholic Steatohepatitis
|
Phase 2 | |
| Completed |
NCT04042142 -
Glucagon Resistance in Patients With NAFLD
|
N/A | |
| Completed |
NCT04657523 -
Ultrasound-Based Liver Fat Quantification (LFQ) Pilot Study
|
N/A | |
| Completed |
NCT04142424 -
A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects
|
Phase 1 | |
| Terminated |
NCT02787304 -
Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)
|
Phase 2 | |
| Recruiting |
NCT04666402 -
Integrated Diagnostics for Early Diagnosis of Liver Disease
|
||
| Completed |
NCT02528305 -
The Effect of HIT in Patients With Non-alcoholic Fatty Liver Disease/Steatohepatitis
|
N/A | |
| Recruiting |
NCT01056133 -
Effect of Fish-oil on Non-alcoholic Steatohepatitis (NASH)
|
Phase 2 | |
| Completed |
NCT02960204 -
Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension
|
Phase 2 | |
| Completed |
NCT04806750 -
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
|
Phase 2 | |
| Recruiting |
NCT05751720 -
Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue
|
Phase 1/Phase 2 |